OR-CIRIUM
3.6.2021 13:02:11 CEST | Business Wire | Press release
Americans are confident to fly again, with 78% of travelers intending to travel for leisure, according to results from a new survey from Cirium , the aviation analytics company. Of those who travel for business, 67% indicate their employer will permit travel in the next three to six months. Some 40% of respondents who intend to return to the skies plan to fly this summer. However, only a small minority had plans to travel by air for major holidays such as the July 4th weekend (16%) and Labor Day weekend (17%).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210603005493/en/
The firm interviewed 2,140 adults across the US between May 11 and 17, 2021, in a nationally representative sample. The margin of error in the reported data did not exceed +/- 3% at the 95% confidence level.
A strong majority of US travelers (90%) intend to fly at some point in the future, and 64% are planning to fly within the next 12 months.
More than three-quarters (78%) of those with plans to travel this year are only planning for domestic trips. Only 22% expect to fly internationally in 2021. The survey also reveals that over one-quarter of respondents reported having taken a flight since the pandemic. Some 60% of respondents indicated that the pandemic will have no impact on their long-term travel plans.
“Cirium’s traveler survey identifies the confidence of the US in flying again, with a majority taking to the skies domestically already—mainly to visit family. The results indicate that the challenges facing US airlines is not lack of travel demand, but on the health and safety measures in place at the airport and in flight,” said Jeremy Bowen, CEO at Cirium.
“US business travel may see some green shoots of recovery in the fall of 2021, as corporations plan to release restrictions on travel.”
While US airlines are increasing domestic flights for summer 2021 and Americans show interest in flying again, travelers expressed health and safety concerns, which impact their travel decisions.
Respondents strongly support the adoption of health passports for future air travel, with 59% supporting a requirement to carry mandatory passes to fly—though 20% disagree with the idea. When asked what airline measures would increase their motivation to fly, the majority of participants identified mandatory mask-wearing (61%) and improved cleaning processes (61%) as the top two measures.
The majority of respondents (78%) identify leisure travel as the main purpose for travel, however the survey reveals optimism for business travel returning in the fall.
Of the respondents who said they travel for business, just 34% were currently permitted to travel by their employer, increasing to 67% within the next three to six months.
The rise in working from home seems to have had little effect on the likelihood to travel for business reasons, as half of US respondents claim there is no change and nearly a quarter (24%) said they are more likely to travel for business.
More than half the respondents reported that they could work remotely and 40% of these respondents claim that the pandemic has increased the chances that they would combine a vacation with work.
Additional insights on air travel in the full report:
- Awareness of new startup airlines in the US
- Long-haul flying on single-aisle aircraft
- Lounge usage and time spent at the airport
- The influence of sustainability concerns on travel
Click here to see the full US Cirium Traveler Intelligence Report.
Complete data with results by age group, US region and gender available on request. Similar data for the UK is available. The survey into traveler sentiment was carried out by independent market intelligence firm AudienceNet on behalf of Cirium.
Ends
For further information please visit www.cirium.com and follow Cirium updates via LinkedIn and Twitter .
About Cirium
Cirium brings together powerful data and analytics to keep the world moving. Delivering insight, built from decades of experience in the sector, enabling travel companies, aircraft manufacturers, airports, airlines and financial institutions, among others, to make logical and informed decisions which shape the future of travel, growing revenues and enhancing customer experiences. Cirium is part of RELX , a global provider of information-based analytics and decision tools for professional and business customers. The shares of RELX PLC are traded on the London, Amsterdam and New York Stock Exchanges using the following ticker symbols: London: REL; Amsterdam: REN; New York: RELX.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210603005493/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
